

AMENDMENTS TO THE CLAIMS:

Claims 1-11. (Canceled)

Claim 12. (Currently Amended) A non-competitive extracellular cytokine receptor antagonist, wherein said antagonist is a peptide ~~containing from about 7 to about 20 of 5 to 20 amino-acids, wherein said peptide comprises a sequence that, over its full length, is at least 82% identical to the amino acid sequence EATVGERVRL (SEQ ID NO:2) of vascular endothelial growth factor receptor (VEGFR), and wherein contacting a cell expressing a VEGFR with said peptide decreases proliferation of said cell relative to a control cell not contacted with said peptide or inhibits neovascularization relative to a control not contacted with said peptide derived from a flexible region of said cytokine receptor.~~

Claims 13-17. (Canceled)

Claim 18. (Currently Amended) A method of inhibiting human VEGFR activity in a cell, ~~said method comprising targeting VEGFR with an antagonist of claim 13 contacting a cell with a peptide of 5 to 20 amino-acids, wherein said peptide comprises a sequence that, over its full length, is at least 82% identical to the amino acid~~

sequence SEQ ID NO:2 of VEGFR,

wherein said peptide inhibiting VEGFR activity is characterized by a decrease in
proliferation of said cell relative to a control cell not contacted with said peptide.

Claims 19-37. (Canceled)

Claim 38. (New) The antagonist of claim 12, wherein said peptide comprises a sequence that contains a substitution, deletion, or addition of one amino acid in the sequence of SEQ ID NO:2.

Claim 39. (New) The antagonist of claim 12, wherein said peptide consists of the amino acid sequence EATVGERVRL (SEQ ID NO:2).

Claim 40. (New) The method of claim 18, wherein said peptide comprises a sequence that contains a substitution, deletion, or addition of one amino acid in the sequence of SEQ ID NO:2.

Claim 41. (New) The method of claim 18, wherein said decrease in proliferation comprises inhibition of neovascularization.